Courtney Flaherty

2 weeks ago | oncnursingnews.com | Courtney Flaherty

The FDA granted fast track designation to ZL-1310, a potential first-in-class DLL3-targeted antibody-drug conjugate (ADC), to treat patients with extensive-stage small cell lung cancer (ES-SCLC).1 The agent is currently being evaluated as both monotherapy and in combination with atezolizumab (Tecentriq) in patients with ES-SCLC in an ongoing, global phase 1 trial (NCT06179069).2 Interim data from the monotherapy dose-escalation portion (part 1a) of the trial presented at the EORTC-NCI-AACR...

2 weeks ago | onclive.com | Courtney Flaherty

The FDA has granted fast track designation to the potential first-in-class DLL3-targeted antibody-drug conjugate (ADC) ZL-1310 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1 ZL-1310 is an investigational ADC that consists of a humanized anti-DLL3 monoclonal antibody attached via a cleavable linker to a novel camptothecin derivative, a topoisomerase I inhibitor.The agent was developed using the TMALIN® ADC platform, which is designed to exploit...

3 weeks ago | ajmc.com | Courtney Flaherty

This article was originally published on OncLive®. Treatment with bexmarilimab (FP-1305) plus standard-of-care (SOC) azacitidine elicited overall responses in patients with relapsed/refractory higher-risk myelodysplastic syndrome (MDS), meeting the primary end point of the phase 2 BEXMAB trial (NCT05428969).1 Additionally, patients with treatment-naive higher-risk MDS treated on the study also experienced a high level of response.

3 weeks ago | onclive.com | Courtney Flaherty

The potential first-in-class EGFR- and HER3-directed bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren; BL-B01D1) demonstrated preliminary responses and a manageable safety profile regardless of HER2 expression in heavily pretreated patients with advanced or metastatic HER2-negative or HER2-low breast cancer, according to initial data from a phase 1 study (NCT05470348) presented during the 2025 ESMO Breast Congress.1 At a median follow-up of 11.7 months, the overall...

3 weeks ago | onclive.com | Courtney Flaherty

As the 2025 ASCO Annual Meeting quickly approaches, several phase 3 breast cancer studies have emerged as major points of interest among oncology professionals. To assess which datasets are generating the most anticipation, OncLive® conducted informal polls on social media, querying breast cancer specialists on X and LinkedIn about the late-breaking abstracts they are most eager to see presented during the meeting.